John Parkinson Email & Phone Number

Glenside, Pa

I am open to consulting opportunities for biotech, pharma, CROs, academia and venture capital

PMFF is a donor-advised charity fund established at the American Endowment Foundation with the goal of providing long term financial support to charities which provide for the education and development of children in poor or developing countries.

Cambridge, Usa

leadership of a multi-platform drug discovery pipeline for IBD and celiac disease therapeutics

• Member, Supervisory Board for Cluster of Excellence - "Inflammation at Interfaces". A 5-year DFG-funded initiative in the State of Schleswig-Holstein, Germany, which encompasses university faculties in Kiel, Lubeck and Borstel. • Provide executive scientific and strategic feedback and decision-making advice, service and endorsement to Steering Committee on research area proposals, progress and overall Cluster performance• Attend annual Cluster conferences and supervisory board meetings

Spring House, Pennsylvania

leadership of a multi-platform drug discovery pipeline for IBD therapeutics

Laval, Quebec, Canada

Leading and build a Center of Excellence in Immunology, Microbiology and Epithelial Cell Biology to drive creation of innovative and transformative therapies for Inflammatory Bowel Disease

Directly supervised 6 PhDs and managed the portfolio of projects executed by 20+ scientific staff at the University of New Mexico Center for Molecular Discovery. UNMCMD is a specialized screening center within the NIH "roadmap" initiative (MLPCN). UNMCMD leverages unique, state-of-the-art high throughput flow cytometry capabilities to screen chemical libraries (>350,000) in 384- and 1536-well platforms in 2 to 6 week turnaround time. It provides service within the US and internationally for researchers seeking to interrogate molecular and cellular pathways via chemical diversity.Reported to Professor Larry Sklar. Major roles and accomplishments were to increase overall group productivity, integrate project management and operational processes and to provide technical and project planning oversight for all RO1 fast track, RO3 and R21 proposals and collaborations fostered by UNMCMD for execution within the MLPCN funding mechanism. Responsible for ensuring annual milestone objectives were met. Represented UNMCD at NIH steering committee meetings. Co-authored the UNMCMD grant renewal proposal in April 2010 which achieved excellent reviews by NIH, was fully funded with a performance bonus award and succeeded in obtaining funding for two center-driven proposals awarded to Dr. George Tegos and Dr. Yang Wu.

•Co-developed with Business Unit Specialized Therapeutics a multi-indication business case strategy for lipoxins. Implemented key investments recommended in the business case via Global Project Team (GPT) and BSP Common Mechanisms Research Dept. Managed all research on lipoxin development program for gastroenterology, which entered phase I trials in 2007. Managed and integrated external KOL-driven collaborations for lipoxin analogs in IBD, allergic airway inflammation, acute inflammation and autoimmunity.• Member, Therapeutic Research Group Inflammation & Immunology (TRG I&I) Management Board - integrated departments in Berlin, Germany and Richmond, USA. Managed small molecule project asset transfer from US to EU and contributed to portfolio prioritization. Chaired the Biologics Strategy Working Group for TRG I&I and recommended strategy to executive management, external KOLs and McKinsey consultants.• Group Leader - IBD Research with 2 PhD reports and 2 associates

• Led R&D program for lipoxins in IBD• Led mechanism & translational research for human GM-CSF in IBD phase II/III studies• Project Leader - LTA4 hydrolase inhibitors in multiple sclerosis. Advanced once daily oral drug to development.• Supervised 2 PhDs/2 associates. Validated kinase target for multiple sclerosis, immunoreceptor target for IBD. Supervised bioinformatics-driven target discovery in macrophages, lymphocytes• Member, Berlex/Pfizer Steering Committee for iNOS inhibitor development• Member 2003, Chair 2004, Berlex Scientific Advisory Committee - annual review of all Berlex portfolio projects• Member 2003-2006 Global Review Committee - lead optimization and drug development candidate proposals • Member 2003-2004 Global Technology Council – Structural Biology• Member 2005-2006 Global Focus Group – Biomarkers• Member 2004, Scientific Advisory Board for NO Society Conference, Nara, Japan.• 8 Patents filed, 20 publications, 10 invited lectures

• Project Leader for lipoxin analogs. Leveraged Brigham & Women's Hospital / Harvard Medical School collaboration to establish efficacy in skin inflammation. Discovered and patented 2nd-generation LX analogs with oral immunomodulatory efficacy in vivo.• Lead biologist in discovering potent, selective iNOS dimerization inhibitors via combinatorial chemistry/rational drug design. Inventor on issued patents for iNOS inhibitors with efficacy in acute and chronic immune disease models. Advanced 2 lead compounds to pre-clinical development.• Managed 1-2 PhD scientists, 1-2 MS-level associates• Member, 1994, 1997, 2001 Berlex Scientific Advisory Committee• Member, 1996 and Chair, 1998, Berlex Project Management Task Force (PMT) - recommended project management system at Berlex• Chair, 2000 Nitric Oxide Society Conference, San Francisco, USA; Member, 2002 Scientific Advisory Board, Nitric Oxide Society Conferences, Prague, Czech Republic• 12 patents filed, 20 publications

Phd

Bsc